Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada.
Shayegan B, Wallis CJD, Malone S, Cagiannos I, Hamilton RJ, Ferrario C, Gotto GT, Basappa NS, Morgan SC, Fernandes R, Morash C, Niazi T, Noonan KL, Rendon R, Osborne B, Park-Wyllie L, Chan KFY, Hotte SJ, Saad F. Shayegan B, et al. Among authors: hotte sj. Urol Oncol. 2022 May;40(5):192.e1-192.e9. doi: 10.1016/j.urolonc.2022.01.009. Epub 2022 Feb 23. Urol Oncol. 2022. PMID: 35216890 Free article.
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Saad F, et al. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. doi: 10.1158/1078-0432.CCR-11-0859. Epub 2011 Jul 25. Clin Cancer Res. 2011. PMID: 21788353 Clinical Trial.
175 results